BioSpace News Archive

Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific MAS Omni Infectious Disease quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B & C virus, Syphilis and HTLV I/II.

On April 1, a dozen anesthesiology resident physicians from Massachusetts General Hospital kicked off an audacious public challenge to design a rapidly deployable, minimum viable ventilator that could address shortages caused by the COVID-19 pandemic, particularly in developing countries.

Based on internal data, 29% of nursing home employees tested positive for antibodies Since the beginning of the COVID-19 pandemic, BioReference has performed 222,000 COVID-19 PCR and 3,500 antibody tests in over 350 facilities

Quantabio , a leading provider of robust DNA and RNA amplification reagents for the most demanding molecular testing and life science research applications, today announced that its UltraPlex 1-Step ToughMix was recognized as part of the expanded emergency use authorization (EUA)

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced that Ton Schumacher, Ph.D., Principal Investigator at the Netherlands Cancer Institute and chair of Allogene’s Scientific Advisory Board, has been award

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com) today announced the official launch of its new RenovaCare R&D Innovation Center in Berlin, Germany, where the Company’s patented technologies for isolating and spraying self-donated stem cells to regenerate tissues and organs have been under development alongside new product initiatives

Designation would provide 10-year period of marketing exclusivity in the European Union after product approval Patients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk myelodysplastic syndromes MENLO PARK, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinio

- U.S. Food and Drug Administration (FDA) has authorized the investigational new drug (IND) application - Acute liver and kidney injury are risk factors for poor outcomes in COVID-19 patients - The risk of death from multi-organ failure is present in both patients with severe COVID-19 and those with severe Alcoholic Hepatitis (AH) - Promising Phase 2a clinical results in patients with AH and pre-clinical evidence in multi-organ injury models suggest DUR-928 may be b

The National Comprehensive Cancer Network® (NCCN®) today announced the completion of the new NCCN Guidelines for Patients®: Immunotherapy Side Effects series, with the publication of a book focused on chimeric antigen receptor (CAR) T-cell therapy.

Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, announced the appointment of Yalonda Howze as Executive Vice President, Chief Legal Officer.